Wellington Shields Capital Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.06M | Sell |
44,831
-2,700
| -6% | -$226K | 0.51% | 39 |
|
|
2026
Q1 | $3.81M | Hold |
47,531
| – | – | 0.57% | 38 |
|
|
2025
Q4 | $4.05M | Hold |
47,531
| – | – | 0.59% | 39 |
|
|
2025
Q3 | $3.7M | Sell |
47,531
-1,500
| -3% | -$117K | 0.56% | 41 |
|
|
2025
Q2 | $3.83M | Sell |
49,031
-5,700
| -10% | -$425K | 0.65% | 35 |
|
|
2025
Q1 | $3.97M | Sell |
54,731
-9,001
| -14% | -$644K | 0.72% | 33 |
|
|
2024
Q4 | $4.72M | Sell |
63,732
-4,100
| -6% | -$287K | 0.83% | 25 |
|
|
2024
Q3 | $4.48M | Sell |
67,832
-11,400
| -14% | -$828K | 0.78% | 24 |
|
|
2024
Q2 | $7.32M | Sell |
79,232
-390
| -0.5% | -$34.5K | 1.33% | 16 |
|
|
2024
Q1 | $7.61M | Sell |
79,622
-2,355
| -3% | -$198K | 1.43% | 16 |
|
|
2023
Q4 | $6.25M | Sell |
81,977
-39,252
| -32% | -$2.73M | 0.78% | 17 |
|
|
2023
Q3 | $8.4M | Buy |
121,229
+175
| +0.1% | +$14.1K | 1.11% | 11 |
|
|
2023
Q2 | $11.4M | Sell |
121,054
-149,581
| -55% | -$13M | 1.39% | 7 |
|
|
2023
Q1 | $10.2M | Buy |
270,635
+12,516
| +5% | +$984K | 1.23% | 7 |
|
|
2022
Q4 | $9.37M | Sell |
258,119
-14,436
| -5% | -$1.11M | 1.14% | 9 |
|
|
2022
Q3 | $10.4M | Sell |
272,555
-21,828
| -7% | -$2.1M | 2.47% | 7 |
|
|
2022
Q2 | $11.9M | Sell |
294,383
-41,034
| -12% | -$4.25M | 1.48% | 7 |
|
|
2022
Q1 | $14.8M | Buy |
335,417
+210,796
| +169% | +$23.6M | 1.61% | 7 |
|
|
2021
Q4 | $16.1M | Sell |
124,621
-2,512
| -2% | -$293K | 2.07% | 8 |
|
|
2021
Q3 | $14.4M | Sell |
127,133
-2,872
| -2% | -$328K | 1.96% | 9 |
|
|
2021
Q2 | $13.5M | Buy |
130,005
+1
| +0% | +$94 | 1.63% | 11 |
|
|
2021
Q1 | $10.9M | Sell |
130,004
-200
| -0.2% | -$16.9K | 1.03% | 17 |
|
|
2020
Q4 | $11.9M | Sell |
130,204
-3,646
| -3% | -$302K | 1.59% | 9 |
|
|
2020
Q3 | $10.7M | Buy |
133,850
+800
| +0.6% | +$62.4K | 1.69% | 7 |
|
|
2020
Q2 | $9.2M | Hold |
133,050
| – | – | 1.48% | 10 |
|
|
2020
Q1 | $8.37M | Sell |
133,050
-2,205
| -2% | -$159K | 1.58% | 9 |
|
|
2019
Q4 | $10.5M | Sell |
135,255
-2,100
| -2% | -$164K | 1.62% | 7 |
|
|
2019
Q3 | $10.1M | Hold |
137,355
| – | – | 1.64% | 6 |
|
|
2019
Q2 | $8.46M | Sell |
137,355
-150
| -0.1% | -$9.07K | 1.4% | 9 |
|
|
2019
Q1 | $8.77M | Hold |
137,505
| – | – | 1.49% | 7 |
|
|
2018
Q4 | $7.02M | Sell |
137,505
-7,500
| -5% | -$379K | 1.33% | 10 |
|
|
2018
Q3 | $8.41M | Hold |
145,005
| – | – | 1.36% | 9 |
|
|
2018
Q2 | $7.04M | Sell |
145,005
-3,315
| -2% | -$155K | 1.16% | 10 |
|
|
2018
Q1 | $6.9M | Hold |
148,320
| – | – | 1.04% | 13 |
|
|
2017
Q4 | $5.57M | Buy |
148,320
+2,100
| +1% | +$77.1K | 0.87% | 15 |
|
|
2017
Q3 | $5.33M | Sell |
146,220
-300
| -0.2% | -$11.4K | 0.87% | 16 |
|
|
2017
Q2 | $5.78M | Buy |
146,520
+81,150
| +124% | +$2.96M | 0.94% | 15 |
|
|
2017
Q1 | $2.05M | Sell |
65,370
-26,385
| -29% | -$826K | 0.33% | 69 |
|
|
2016
Q4 | $2.87M | Buy |
91,755
+45,855
| +100% | +$1.49M | 0.48% | 45 |
|
|
2016
Q3 | $1.84M | Buy |
45,900
+1,200
| +3% | +$45.2K | 0.32% | 70 |
|
|
2016
Q2 | $1.49M | Sell |
44,700
-15,000
| -25% | -$513K | 0.25% | 83 |
|
|
2016
Q1 | $1.75M | Buy |
+59,700
| New | +$1.65M | 0.31% | 72 |
|
Other funds holding EW
Wellington Shields Capital Management's EW Position: Q2 2026 in Review
Wellington Shields Capital Management reduced its Edwards Lifesciences (EW) stake by 5.7% in Q2 2026, selling an estimated $226K and leaving 44,831 shares worth $4.06M. The position accounts for 0.51% of the portfolio, ranked #39.
Wellington Shields Capital Management first reported a position in EW in Q1 2016 and has held it in 42 quarters since. The position peaked at $16.1M in Q4 2021. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Wellington Shields Capital Management held 44,831 shares of Edwards Lifesciences worth $4.06M as of Q2 2026.
- Wellington Shields Capital Management sold 2,700 Edwards Lifesciences shares in Q2 2026, an estimated $226K.
- Edwards Lifesciences made up 0.51% of Wellington Shields Capital Management's portfolio in Q2 2026, its #39 holding.
- Wellington Shields Capital Management first reported a position in Edwards Lifesciences in Q1 2016 and has held it in 42 quarters since.
- Wellington Shields Capital Management's Edwards Lifesciences position peaked at $16.1M in Q4 2021.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Wellington Shields Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.